Axial psoriatic arthritis: An update for dermatologists - 05/12/20
Abstract |
Psoriasis is a chronic, immune-mediated, systemic, inflammatory disorder characterized by skin plaques and, often, nail disease and arthritis that contribute to reduced quality of life. Psoriatic arthritis—a heterogeneous, inflammatory, musculoskeletal disease that can cause permanent damage to both peripheral and axial joints—is the most common comorbidity of psoriasis. Axial disease occurs in 25% to 70% of patients with PsA, with some patients exclusively experiencing axial joint involvement. Early therapeutic intervention is important for preventing permanent joint and spine damage and loss of functionality in these patients. Because skin symptoms associated with psoriasis often precede psoriatic arthritis, dermatologists are uniquely positioned to play an important role in identifying and treating patients with psoriatic arthritis. Proactive screening of patients with all severities of psoriasis for the signs and symptoms of psoriatic arthritis is key to early diagnosis and intervention. In this review, we discuss the clinical presentation, risk factors, and treatment options for psoriatic arthritis with axial involvement, with the aim of helping dermatologists understand the disease and identify patients who might benefit from further assessment, treatment, and/or referral to a rheumatology practice.
Le texte complet de cet article est disponible en PDF.Key words : axial disease, inflammatory arthritis, inflammatory back pain, psoriasis, psoriatic arthritis
Abbreviations used : AS, axSpA, DMARD, HLA, IBD, IL, NSAID, PASI75, PsA, QOL, SpA, TNF, TNFi
Plan
Funding sources: Supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ. |
|
Disclosure: Dr Gottlieb has served as a consultant and/or as an advisory board member for Avotres Therapeutics, Beiersdorf, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Incyte, Leo Pharmaceutical Industries, Lilly, Novartis, Sun Pharma, UCB, and XBiotech; has received research or educational grants from Boehringer Ingelheim, Incyte, Janssen, Novartis, UCB, and XBiotech; and holds stock options with XBiotech. Dr Merola has served as a consultant for AbbVie, Biogen Idec, Celgene, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Samumed, Sanofi Regeneron, Science 37, and UCB; as an investigator for Biogen Idec, Incyte, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie. |
|
IRB approval status: Not applicable. |
|
Reprints not available from the authors. |
Vol 84 - N° 1
P. 92-101 - janvier 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?